

About the Editors

Abraham J. Domb is a Professor for Medicinal Chemistry and Biopolymers at the Faculty of Medicine of the Hebrew University, Jerusalem, Israel. He earned Bachelor's degrees in Chemistry, Pharmacy and Law studies and Ph.D. degree in Chemistry from Hebrew University. He did his postdoctoral training at MIT and Harvard University, USA, and was R&D Manager at Nova Pharm. Co., Baltimore, USA, during 1988–1992. During 2007–2012 he headed the Division of Identification and Forensic Sciences of the Israel Police. His primary research interests are in biopolymers, controlled drug delivery, cancer therapy, nanoparticulate systems, and forensic sciences.

Wahid Khan obtained his Master's and Ph.D. in Pharmaceutics at the National Institute of Pharmaceutical and Educational Research (NIPER), Mohali, India, and worked with Prof. Abraham J. Domb at the Hebrew University of Jerusalem, Israel, for his postdoctoral research. Currently, he is working as an Assistant Professor in the Department of Pharmaceutics, NIPER, Hyderabad, India. He is having experience of working in areas of drug delivery, drug targeting, nanomedicine, and biodesign of implantable medical devices. Dr. Khan has also won various national and international awards and fellowships including Israel government prestigious PBC fellowships for outstanding postdoctoral researcher and Valazzi-Pikovsky and Lady Davis fellowship award.

Index

A

- Abdullah, S., 9
- Abrishami, M., 233
- Acne ramification, pathogenic cascade in, 551
- Actisite®, 290–291
- Active lymphatic targeting, 436
- Active targeting, 63, 64, 515
- liposomes, 104–105
 - of nanoparticles, 524
- Adipose-derived stem cells, for wound healing, 598
- Affinity-binding alginate delivery system
- alginate sulfation, 497
 - growth factor release and bioactivity, 498–499
 - protein binding, 497, 498
- Agarwal, S., 639
- Ajili, S.H., 37
- Alginates, 8
- for osteochondral repair/regeneration, 490
 - osteomyelitis, 467
- Ali, J., 333
- Amiji, M., 359–380
- 5-Aminolevulinic acid, 549
- Amorolfine lacquer, 577
- Anderson, J.M., 413
- Andukuri, A., 37
- Angiogenesis, 66–67
- brain tumors, 184–185
 - factors for inducing bone regeneration, 485
- Antiacne nanotherapeutics, 551–552
- Anti-ageing nanotherapeutics
- antioxidants, 552
 - ascorbic and retinoic acid, 553
 - carbon nanodelivery systems, 553
 - coenzyme Q10, 552
 - metaloxide-based nanodelivery systems, 553
 - micellar lecithin organogel, 553
 - sunscreen agents, 554
- Antibacterial nanotherapeutics, 544–546
- Antibiotics
- osteomyelitis
 - fluoroquinolones, 462
 - goals, 461
 - local antimicrobial agent delivery, 461
 - polymers for, 462, 463
 - for wound healing, 594–595
- Antibody-based targeting, 79–81
- Anticancer drug delivery systems
- microparticles and nanoparticles for, 523–525
 - passive targeting vs. active targeting strategies, 64
 - systemically administered
 - enhanced permeability of tumor, 158
 - intratumoral disposition, 156–158
 - pathways, 155–156
 - rational design, 158–160
 - strategies, 156
- Antifungal nanotherapeutics, 546–547
- Antimicrobial peptides (AMP), 313–314
- Antioxidants
- anti-ageing, 552
 - wound healing, 598
- Antiparasitic nanotherapeutics, 548
- Antiplateau agents
- antimicrobial peptides, 313–314
 - chemoprophylactic agents, 312–313
 - probiotic therapy, 315
 - sugar substitutes, 315–316
 - vaccines, 314–315

- Antiproliferative nanotherapeutics, 548
 5-aminolevulinic acid, 549
 magnetic nanoemulsions, 550
 nitric oxide, 550
 psoralen, 549
 TyroSpheres™, 549, 550
- Antiviral nanotherapeutics, 547
- Aptamer-based targeting ligand, 77
- Arabinogalactan, 11
- ARESTIN®, 292
- Arifin, D.Y., 162
- Arndt-Jovin, D.J., 182
- Arriaga, M.A., 220
- Arterial diseases
 endothelium in vascular homeostasis, 361–362
 nanotechnology, for drug delivery
 imaging and image-guided therapy, 379–380
 nucleic acid delivery, 378–379
 in small molecule drug delivery, 378
 pathophysiology
 arteriogenesis, 366–367
 atherosclerosis, 365
 carotid arterial disease, 367
 coronary arterial disease, 367–368
 inflammation, 363–364
 peripheral arterial disease, 367–368
 primary causes, 362
 restenosis, 365–366
 schematic illustration, 362–363
 thrombosis, 364
 treatment of, 368
 systemic vs. local therapeutic strategies
 pharmacological drug classes, 368–369
 rationale for local drug delivery, 369–370
 stent therapy, 370–377
 tissue structure and function, 360–361
- Articular cartilage, 480, 482, 493, 503
 in arthritic joints, 476
 BMP-7, 483
 calcified zone, 475
 deep zone, 475
 description, 474
 functions, 476
 IGF-1, 483
 lesions, 477
 middle zone, 475
 subchondral bone, 476
 superficial zone, 475
 ultrastructure, 474
- Aselli, G., 430
- ATP-binding cassette (ABC) superfamily, 348
 MRP2, 350–352
 P-glycoprotein, 349–350
- Autologous chondrocyte implantation (ACI)
 first-generation, 479
 second-generation, 479–480
- Ayurvedic herbal plants, for wound healing, 600
- B**
- Bainbridge, J.W., 251
- Baji, A., 639
- Ball, C., 634
- BaMaran, E., 234
- Bare-metal stent (BMS), 370, 388
- Bargoni, A., 439
- Barnes, C.P., 417
- Basic fibroblast growth factor (bFGF), for wound healing, 597
- BATT. *See* Boosted antifungal topical treatment (BATT)
- Belanyx® lotion, 572
- Benny, O., 181
- Berger, M.S., 171
- Bevacizumab, 185
- Beyth, N., 285–299, 305–323
- Bhatnagar, 440
- Bhowmik, B.B., 8
- Bilayered scaffold, for osteochondral tissue engineering
 bilayered in vitro system, construction of, 502–503
 spatial differentiation, of hMSCs, 499–500
 TGF- β 1 and BMP-4 activity, 500–502
- Bioabsorbable drug-eluting stent (DES), 396–398
- Biocompatibility, 47
- Biodegradable implants, osteomyelitis
 natural polymers
 alginates, 467
 chitosan, 467
 collagen, 466–467
 gelatin, 467
 poly(orthoesters), 466
 poly(sebacic-co-ricinoleic-ester-anhydride), 465–466
 poly(trimethylene carbonate), 464–465
 poly- ϵ -caprolactone, 465
 polylactides, 463–464
- Biodegradable polymers
 natural polymers, 4
 alginates, 8
 arabinogalactan, 11
 chitosan, 9–10

- collagen, 5–6
 - dextran, 9
 - fibrin, 7
 - gelatin, 6–7
 - polyhydroxyalkanoates, 11
 - silk fibroin, 8
 - synthetic polymers
 - (*see* Synthetic polymers)
 - Biodegradable stents, 376–377
 - Biofilms
 - control of, 309–310
 - dental caries, 308
 - endodontic infections, 308–309
 - formation and characteristics of, 306–307
 - periodontal and peri-implant diseases, 308
 - Biomaterial-based delivery systems, for
 - osteochondral repair/regeneration
 - alginate sulfation, 497
 - in animal models, 491, 492
 - bilayered/gradient scaffolds, 494–495
 - ceramics, 491
 - design of
 - bioactive factor incorporation, 488
 - biocompatibility, 486
 - biodegradation/bioresorption, 487
 - gradient/layered/biphasic systems, 487–488
 - internal morphology, 487
 - mechanical strength and product fabrication, 487
 - schematic illustration, 486
 - surface properties, 487
 - glycosaminoglycans, 497
 - growth factor release and bioactivity, 498–499
 - injectable hydrogels
 - BMP-2/BMP-4, 496
 - description, 495
 - self-assembling peptide sequence, 496–497
 - stromal cell-derived factor-1, 496
 - natural-based polymers
 - alginate, 490
 - collagen, 488
 - gelatin, 490
 - hyaluronan, 490
 - single-layered scaffolds, 492–494
 - surface plasmon resonance, 497, 498
 - synthetic polymers, 490–491
- Biotherapeutics, carriers for lymphatic targeting, 445
- Bishara, A., 14
- BOAT. *See* Boosted oral antifungal therapy (BOAT)
- Bochot, A., 233
- Bone infections. *See* Osteomyelitis
- Bone marrow-derived mesenchymal stem cells, for wound healing, 597
- Bone morphogenic proteins (BMP)
 - factors inducing bone regeneration, 484
 - factors inducing cartilage regeneration, 483
- Boosted antifungal topical treatment (BATT), 569
- Boosted oral antifungal therapy (BOAT), 569
- Botelho, M.F., 439
- Bourges, J-L., 228
- Bow, H., 169–186
- Bradykinin (BK), 67–69
- Brain tumor. *See* Glioblastoma multiforme (GBM)
- Breen, A., 7
- Brem, H., 169–186
- Brin, Y.S., 459–469
- Brittberg, M., 479
- Burns. *See also* Wounds
 - antimicrobials, 595
 - antioxidant treatment, 598
 - classification, 589
 - hydrocolloid dressings, 591
 - minocycline-incorporated dressings, 592
 - pathophysiology, 588
 - phenytoin, 599
 - umbilical cord-derived stem cells, 597
 - vitamin A/C incorporated collagen sheet dressings, 593
- Burst effect, 161
- Byrne, R.A., 398
- Bystander effect, 185
- C**
- Cai, S., 9, 441
- Calcium phosphate-based systems, 311–312
- Calvo, P., 232
- Camenzind, E., 406
- Camptothecin (CPT), 128–129, 131
- Carbohydrates-based targeting ligands
 - galactose, 78
 - mannose, 78–79
- Carbon nanotubes (CNT), 442–443
- Carlson, E.C., 251
- Carmustine, 178
- Carriers for lymphatic targeting
 - colloidal carriers, 436–437
 - emulsifying drug delivery systems, 437
 - liposomes, 438–439
 - nanocapsules, 440
 - solid lipid nanoparticles, 439–440

- Carriers for lymphatic targeting (*cont.*)
- miscellaneous carriers
 - antibody-drug conjugates, 443–444
 - biotherapeutics, 445
 - carbon nanotubes, 442–443
 - dendrimers, 441–442
 - hybrid nanosystems, 444–445
 - polymeric carriers
 - natural, 440–441
 - synthetic, 441
 - strategies for nanocarriers, 436–437
 - surface modification with
 - biotin, 449, 550
 - ligands, 448–449
 - polyethylene glycols, 447–448
- Carvalho, G.J., 222
- Castro, G.A., 551
- Cationic nanoemulsion technology, 229–230
- Cavalli, R., 234
- CEDD. *See* Convection-enhanced drug delivery (CEDD)
- Cell-penetrating peptides (CPPs), 97
- Cell therapy, for osteochondral repair
 - autologous chondrocyte implantation
 - first-generation, 479
 - second-generation, 479–480
 - stem cell-based strategies
 - human embryonic stem cells, 480
 - mesenchymal stem cells, 480–481
- Chaichana, K.L., 180
- Challa, V.G.S., 3–24, 459–469
- Chan, J.M., 16
- Chandy, T., 416
- Chaowanachan, T., 626
- Chemoprophylactic agents, 312–313
- Chemotherapy
 - glioblastoma multiforme, 171–172
 - skin cancer, dermatological applications, 270
- Chen, M., 638
- Chen, S.H., 445
- Chenchen, Y., 77
- Cheng, K., 243–259
- Chiappetta, D.A., 544
- Chitosan, 9–10, 467
- Choi, H.K., 576
- Christy, N., 445
- Chun, C., 526
- Cierny, G.I.I.I., 460
- Clearway™ RX system, 370
- Clotrimazole lacquer, 574
- Coaxial electrospinning process, 633
- Cobalt–chromium alloys, 39–40
- CODES, 347–348
- Cohen, S., 473–506
- Coley, W., 183
- Collagen, 466–467
 - for osteochondral repair/regeneration, 488
 - uses of, 5–6
- Colloidal carriers, 436–437
 - emulsifying drug delivery systems, 437
 - liposomes, 438–439
 - nanocapsules, 440
 - solid lipid nanoparticles, 439–440
- Colon, J., 553
- Composite scaffolds, 468
- Controlled focal drug delivery, 319–320
- Convection-enhanced drug delivery (CEDD), 176–177
- Coronary artery diseases, 389
- Corrosion, 46–47
- Cross-linked polymers, 121
- Csaba, N., 16
- Cu, Y., 624
- Cuneo, K.C., 175
- Curcio, A., 393
- Cutisorb™, 592
- Cx43, for wound healing, 599–600
- Cyclodextrin-based polymer (CDP), 130
- CYP3A4 gradient, 353–354
- Cytokines, for wound healing, 595
- D**
- Daenen, L.G., 528
- Dahan, A., 329–338, 343–355
- Das Neves, J., 623, 624, 628
- Davis, P.B., 23
- de Duve, C., 119
- Del Gaudio, C., 420
- D’Emanuele, A., 137
- Dendrimers
 - carriers for lymphatic targeting, 441–442
 - nanotechnology-based ophthalmic drug
 - delivery system, 231–232
 - polymer–drug conjugate, 121–122
- Dental caries, 308
- Dentifrices, 317
- Dentomycin®, 292
- Dermatological applications
 - atopic dermatitis, 269–270
 - E-selectin antagonist CGP69669A, 269–270
 - herpes labialis, 272–273
 - hyperhidrosis, 273–274
 - local anesthesia, 268
 - methotrexate, 269
 - psoriasis, 268–269
 - skin cancer
 - chemotherapy, 270
 - photodynamic therapy, 271–272

- Desai, P.P., 535–555
- Deshpande, D., 359–380
- Destache, C.J., 628
- Dextran, 9
- Diabetic ulcers, 588, 599. *See also* Wounds
- 1,2-Diaminocyclohexane (DACH), 129
- Dickinson, P.J., 176
- Diebold, Y., 233
- Dilnawaz, F., 225–237
- DiResta, G.R., 84
- Distal and lateral subungual onychomycosis (DLSO), 566, 567
- Di-/tri-/ and multiblock copolymer systems, 520
- Domb, A.J., 3–24, 33–55, 61–85, 133, 195–211, 285–299, 387–399, 459–469, 511–529, 585–600
- Dorsal nail plate surface, 564, 565
- Doxorubicin (DOX)
cytotoxicity, 524
polymer–drug conjugate, 128
- Dressings, for wound healing
classification, 590
medicated dressing
antimicrobials, 592
collagen-hyaluronic acid matrix, 593
copper-based dressings, 593
growth factors, 593
vitamin A, C and E, 593
non-medicated dressings, 590
alginate dressings, 591
hydrocolloid dressings, 591
hydrogel dressings, 591–592
properties, 589–590
- Drug delivery
vehicles
calcium phosphate apatite matrix, 667–668
cyclodextrins, 665
hybrid formulations, 666–667
hydrogels, 664
injectable lipid matrix, 666
injectable liquid polymers, 665–666
lipid-protein-sugar particles, 663
liposomes, 660–661
lipospheres, 663
particulates, 659–660
synthetic hydrophobic polymers, 661–663
to wound healing
antibiotics, 594–595
antihistamines, 599
antioxidants, 598
ayurvedic herbal plants, 600
connexin-targeted antisense gel, 599–600
dressings, 589–593
gabapentin, 599
gene therapy and cytokines, 595–596
growth factors, 596–597
nutritions, 599
phenytoin, 599
reactive oxygen species, 598
stem cells, 597–598
traditional drugs, 600
- Drug delivery systems. *See also* Polymer-based drug delivery systems
anticancer
microparticles and nanoparticles for, 523–525
particulate drug delivery, 523
for cancer treatment, 512, 514
intravaginal, 612
vagina (*see* Vaginal drug delivery systems)
- Drug-eluting balloons, 370
- Drug-eluting stents (DES)
bare-metal stent, 387
design of
computational fluid dynamics, 390
figures of merit, 390
stent coating, 391
stent platform, 390–391
therapeutic agent, 391–393
development of
first-generation, 388–389
fourth-generation, 389–390
second-generation, 389
third-generation, 389
future aspects
bioabsorbable DES, 396–398
dual DES, 398
nanoscale surface modifications and gene delivery, 398–399
polymer-free DES, 395–396
guidelines, 393
European, 394–395
UK, 394
US, 394
safety and efficacy, 393
stent therapy for arterial diseases, 370–371
- Drug penetration, tumor environment effect, 512, 513
- Dual drug-eluting stent (DES), 398
- Dual growth factor delivery system, for osteochondral regeneration
bilayered scaffold, 499–503
injectable bilayer system, 503–505
- Duan, J., 72
- Duncan, R., 119
- Dunne, A.A., 441
- Dutta, T., 629

E

- EcoNail™, 574
- Edelman, E.R., 406, 414
- Einmahl, S., 18
- Elastic modulus, 45–46
- Elastin-like polypeptides (ELPs), 521–522
- Electrospinning process, 635–640
 - advantages, 633
 - coaxial, 633
 - description, 631
 - features, 631, 632
- Elgart, A., 11
- Ellington, A.D., 77
- Emulsifying drug delivery systems, 437
- Endodontic infection
 - vs. intracanal medicament, 322–323
 - vs. irrigation regimes, 322
 - root canal system cavity, 321–322
- Endonyx onychomycosis (EO), 567
- Enhanced permeability and retention (EPR) effect
 - discovery, 65
 - endogenous factors, 68
 - bradykinin, 67–69
 - matrix metalloproteinases, 70
 - nitric oxide, 69
 - peroxynitrites, 70
 - prostaglandins, 69–70
 - vascular endothelial growth factor, 70–71
- PDC, 134
- tumor microenvironment features
 - abnormal lymphatic drainage, 67
 - angiogenesis, 66–67
- Ensign, L.M., 624
- Epidermal growth factor receptor (EGFR), 186
- Epithelial stem cells, for wound healing, 598
- Essex, S., 93–110
- Eszterhas, S.K., 627
- European guidelines, DES, 394–395
- Evans, T.N., 609
- Expendable systems, GRDF, 334–335
- Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS), 134
- Eye structure, ocular nucleic acid delivery
 - anterior segment
 - aqueous humor, 246
 - conjunctiva, 245–246
 - cornea, 244–245
 - iris, 246
 - lens, 246

- posterior segment
 - Bruch's membrane, 247
 - retina, 247
 - sclera, 246–247
 - vitreous humor, 248
- schematic diagram, 244–245

F

- Fang, Y.P., 549
- Farah, S., 387–399
- Fassihi, R., 334
- Fatigue, 46
- Fatty acid-based polymers, 522–523
- FDA-approved implantable medical devices, 50–54
- Fibrin, 7
- Fibroblast growth factors (FGF), 484
- Fillmore, H.L., 182
- Finite element 3D model of brain, 162
- First-degree wounds/burns, 585, 588, 589
- First-generation DES, 388–389
- Floating systems, GRDF, 333–334
- Fluconazole, for onychomycosis, 568
- Fluorides, remineralization agents, 310–311
- Fluoroquinolones, 462
- Focal drug delivery
 - vs. caries lesions
 - antiplaque agents, 312–316
 - remineralization agents, 310–312
 - vs. endodontic infection
 - intracanal medicament, 322–323
 - irrigation regimes, 322
 - root canal system cavity, 321–322
 - vs. periodontal and peri-implant infection
 - alveolar bone loss and pocket formation, 316
 - anti-infective phase, 317
 - challenges in peri-implant infection, 320–321
 - controlled focal drug delivery, 319–320
 - dentifrices, 317
 - healthy tooth and periodontium morphology, 316
 - mouth rinse agents, 317–318
- Focal drug delivery
 - controlled, 319–320
 - glioblastoma multiforme
 - CEDD, 176–177
 - implantable catheter systems, 175–176
 - nail diseases
 - nail psoriasis, 570–571
 - onychomycosis (*see* Onychomycosis)
 - symptoms, 565–566

- topical ungual formulations, 571–576
 - treatment, 566, 576–579
 - nail unit
 - composition and function, 561, 562
 - hyponychium, 563
 - nail bed and fold, 563
 - nail matrix, 561, 563
 - nail plate, 563–565
 - schematic diagram of, 561, 562
 - Folate-linked nanocarrier systems (FA-NS), 72, 76–77
 - Folkman, J., 177, 184
 - Fourth-generation DES, 389–390
 - Frenkel, V., 99
 - Fullerenes, for antiacne activity, 551
 - Full-thickness wounds/burns.
 - See* Third-degree wounds/burns
- G**
- Galactose, 78
 - Gander, B., 415
 - Gastroretentive dosage forms (GRDF)
 - advantages, 330
 - controlled release formulation, 330
 - development of, 332
 - drugs for, 331
 - factors, 330
 - features, 331
 - local *Helicobacter pylori*-related pathologies, 336–337
 - types of
 - expendable systems, 334–335
 - floating systems, 333–334
 - high-density systems, 333
 - magnetic systems, 336
 - mucoadhesive/bioadhesive systems, 335
 - schematic description, 332
 - superporous hydrogels, 335
 - Gelatin, 6–7, 467, 490
 - Gelfoam[®], 6
 - Gels, 289
 - Gene-eluting stents, 377
 - Gene therapy, for wound healing, 595–596
 - GENIE[™] catheter system, 370
 - GENTA-COLLr, 298
 - Gil-Alegre, M., 181
 - Gliadel
 - clinical testing, 178–180
 - efficacy of, 180–181
 - Glioblastoma multiforme (GBM)
 - blood–brain barrier, 174
 - challenges in therapy, 174–175
 - controlled-release polymers, 177–178
 - epidemiology, 170
 - focal drug delivery systems
 - CEDD, 176–177
 - implantable catheter systems, 175–176
 - gliadel
 - clinical testing, 178–180
 - efficacy of, 180–181
 - micro-and nanospheres, 181–182
 - microchips, 182–183
 - nanoparticles, 182
 - non-focal therapies
 - angiogenesis inhibitors, 184–185
 - gene therapy, 185
 - immunotherapy and tumor vaccines, 183–184
 - monoclonal antibodies, 186
 - small-molecule inhibitors, 186
 - treatment
 - chemotherapy, 171–172
 - radiation therapy, 172–173
 - surgical resection, 170–171
 - tumor microenvironment, 174
 - Glucocorticoids, 571, 656
 - Goldman, S., 220
 - Gooding, C.R., 479
 - Gratieri, T., 263–280
 - Greco, F., 126
 - Gunaseelan, S., 629
 - Gunatillake, P.A., 21
- H**
- Hadelsberg, U., 169–186
 - Haemocompatibility, 36
 - Hafez, E.S.E., 609
 - Hagigit, T., 230
 - Ham, A., 628
 - Han, J., 405–423
 - Haramaty, O., 305–323
 - Hashida, M., 78, 437
 - Hauss, D.J., 437
 - Hbaieb, S., 546
 - High-density systems, GRDF, 333
 - High energy focused ultrasound (HIFU)-mediated liposomal FDD, 99–101
 - Highly active antiretroviral therapy (HAART), 626
 - High-performance polyimide microlumen (HPPM), 221
 - Hillaireau, H., 547
 - Hirnle, P., 438
 - Holland, T.A., 495
 - Hopkins, J., 180

- Hoque, M.E., 17
hPepT1, 352–353
Huang, C., 444, 633, 639
Huang, S-L., 107
Hui, X., 575
Human bone-derived cells (HBDC), 21
Human embryonic stem cells (hESC), 480
Huntington, G.C., 430
Husmann, K.R., 220
Hyaluronan, 490
Hyaluronic acid (HA), 124
- I**
- Ibsen, S., 102
Immunization, 315
Implantable catheter systems, 175–176
Implantable medical devices
 applications
 drug delivery and scaffolds, 48–52
 structural and mechanical support, 50, 53–54
 cardiovascular implants, 35–37
 class I devices, 34–35
 classification of, 36
 class II and III devices, 35
 cochlear implant, 38
 corrosion and biocompatibility, 46–47
 materials used for
 biodegradable polymers, 42–44
 ceramics and composites, 44
 drugs, 44–45
 metals, 39–40
 non-biodegradable polymers, 42
 mechanical properties
 elastic modulus, 45–46
 fatigue, 46
 yield strength, 45
 orthopaedic implants, 37–38
 sterilisation, 47–48
Infections
 bone (*see* Osteomyelitis)
 sterilisation, 47–48
Injectable bilayer system, for osteochondral repair and regeneration, 503–505
Inner ear therapy
 advantages and disadvantages, 222–223
 anatomy, ear, 215
 intratympanic perfusion
 trans-eustachian tube catheter injections, 218–219
 transtympanic catheter injections, 218
 transtympanic needle injections, 217
 NANOI project, 222
 organ-targeted delivery
 oval window diffusion-polyimide microlumen, 221
 round window diffusion-gelatine sponge, 220
 round window diffusion-microwick device, 219, 220
 tympanic medial wall diffusion, 221–222
Innocente, F., 419, 421
In situ forming hydrogels, 667
In-stent restenosis (ISR), 34, 370
Insulin-like growth factor-1 (IGF-1), 483–484
Integumentary system. *See* Skin
Intestinal tract
 classification, 343
 CYP3A4 gradient, 353–354
 membrane transporters
 ABC superfamily, 349–352
 drug absorption, 349
 influx and efflux transport, 348
 schematic diagram, 349
 SLC, 348, 352–353
 pH values
 CODES, 347–348
 extent of ionization, 345
 metoprolol, 345
 permeability measure, 345–346
 pH-sensitive radio-transmitting capsule, 344
 sotalol, 346
Intracavitary balloon catheters, 175
Intralesional drug therapy, of nail psoriasis, 570–571
Intranasal nanoparticles, 196
Intraoperative MRI, brain tumor, 171
Intratumoral disposition
 focal anticancer drug delivery, 161, 162
 systemically administered anticancer DDSs, 156–158
Intratympanic perfusion
 trans-eustachian tube catheter injections, 218–219
 transtympanic catheter injections, 218
 transtympanic needle injections, 217
Intravaginal drug delivery system, 612
Intravaginal rings (IVRs), 616–618
Inui, S., 551
Iontophoresis, 230–231, 577
 ocular
 current density, 276–277
 EyeGate® II delivery system, 275–276
 schematic illustration, 275–276
 transcorneal iontophoresis, 277–278
 transscleral iontophoresis, 278–280

- topical skin treatments
 - cosmeceutical applications, 274–275
 - dermatological applications, 268–274
 - devices, 268
 - histology, 267
 - transport mechanisms
 - advantages and disadvantages, 264–265
 - Ag/AgCl electrode system, 264–265
 - electromigration, 266
 - electroosmosis, 266–267
 - passive diffusion, 266
 - Itching, 599
 - Itoh, A., 216
 - Itoi, E., 496
 - Itraconazole, for onychomycosis, 568
- J**
- Jaffe, M., 33–55
 - Jain, S., 585–600
 - Jamal-Allial, A., 359–380
 - Jamming effect, 158
 - Jannesari, M., 636
 - Jasti, B., 466
 - Jaygopal, A., 236
 - Jeong, B., 516
 - Jiang, X., 21
 - Jiaravuthisan, N.M., 570
 - Johnston, M.R., 441
- K**
- Kalia, Y.N., 263–280
 - Kantelhardt, S.R., 182
 - Karp, J.M., 15
 - Kawakami, S., 233
 - Kayaci, F., 640
 - Khan, W., 3–24, 33–55, 117–141, 285–299, 387–399, 429–450, 459–469
 - Khatri, K., 444
 - Khor, E., 467
 - Kilfoyle, B.E., 549
 - Kim, G.Y., 183
 - Kim, H., 236
 - Kim, J.S., 419
 - Kim, S.W., 519
 - Klausner, E.A., 335
 - Kleinedler, J.J., 398
 - Klibanov, A.L., 101
 - Knudsen, N., 549
 - Kobayashi, H., 441, 442
 - Kohane, D.S., 523
 - Kohn, J., 22
 - Kokkoli, E., 81
 - Kolachalama, V.B., 390
 - Kopecek, J., 119, 140
 - Krogstad, E.A., 607–641
 - Kubek, D.J., 195–211
 - Kubek, M.J., 195–211
 - Kumanohoso, T., 441
 - Kumar, D., 117–141
 - Kumar, N., 61–85, 585–600
 - Kyun, K.D., 17
- L**
- Lacquers
 - definition, 573
 - nail (*see* Nail lacquers)
 - Lactoferrin, 83
 - Lai, C.H., 78
 - Lai, S.K., 623
 - Lalwani, A.K., 222
 - Langer, R., 3–24, 177
 - Latimer, P., 438
 - Laurencin, C.T., 466
 - Lauric acid, for antiacne activity, 551
 - Lawson, K.A., 438
 - Lee, V.H.L., 611
 - Lei, L., 372, 374
 - Lelkes, P.I., 405–423
 - Leong, K.W., 178
 - Levi, Y., 395
 - Li, X., 636
 - Li, Y., 183
 - Liao, H., 465
 - Lidar, Z., 177
 - Ligand targeting systems
 - cancer therapy, 73, 75
 - small molecules
 - antibodies, 79–81
 - aptamer, 77
 - carbohydrates, 78–79
 - folate-linked nanocarrier system, 72, 76–77
 - glycoproteins, 82–83
 - peptides, 81–82
 - types of, 71
 - Light-responsive liposomes, 106–107
 - Lim, H.J., 415
 - Ling, S., 438
 - Liposomal focal drug delivery
 - advancements in, 96
 - gene delivery, 97–98
 - intracellular liposomal delivery, 96–97
 - long-circulating liposomes, 95–96
 - benefits vs. limitations, 107, 108

- Liposomal focal drug delivery (*cont.*)
 HIFU, 99–101
 LFU, 101–103
 liposomes as tool, 98
 non-cancer therapy setting
 cardiovascular disorders, 107–109
 cerebrovascular disorders, 110
 ocular disorders, 109
 tissue-specific siRNA delivery, 109
 ultrasound contrast agents, 110
 US-mediated liposomal FDD
 actively targeted liposomes, 104–105
 light-responsive liposomes, 106–107
 magnetic liposomes, 106
 pH-sensitive liposomes, 105–106
 redox potential-sensitive liposomes, 106
- Liquid vaginal dosage forms, 616, 617
- Liu, F., 218
- Liu, L., 9
- Liu, W.G., 522
- Liu, X.W., 496
- Liu, Z., 234, 336
- Local anesthetics, PDLA
 conventional, 655–656
 nonconventional, 656–658
- Local drug delivery
 cardiovascular disorders
 (*see* Arterial diseases)
 fabrication of, 462, 463
 oral cavity
 cold sores/herpes labialis, 294–295
 extraction wounds, 298
 liquid dosage, 289–290
 mouth ulcers, 293–294
 oral infections, 297
 oral malodor, 295–296
 periodontitis, 290–292
 requirements for, 286
 semisolid dosage, 289
 solid formulations, 286–289
 xerostomia, 298–299
- Locally injectable polymeric DDS
 elastin-like polypeptides, 521–522
 fatty acid-based polymers, 522–523
 thermosensitive sol–gel reversible hydrogels, 515–521
- Long-circulating liposomes, 95–96
- Lopez, K.A., 176
- Lower critical solution temperature (LCST)
 thermosensitive hydrogels
 di-/tri-/ and multiblock copolymer systems, 520
- OncoGel™, 519
- PLGA–PEG–PLGA triblock copolymers, 519
- pluronic hydrogels, 518–519
 poly(*N*-isopropylacrylamide), 518
 poly(organophosphazenes), 520–521
 ReGel®, 519
 theragnostic hydrogel, 521
- Low focused ultrasound (HIFU)-mediated liposomal FDD, 101–103
- Lozenges, 288–289
- Luong-Van, E., 419
- Lymphatic targeting
 active targeting, 436
 colloidal carriers, 436–437
 emulsifying drug delivery systems, 437
 liposomes, 438–439
 nanocapsules, 440
 solid lipid nanoparticles, 439–440
 miscellaneous carriers
 antibody-drug conjugates, 443–444
 biotherapeutics, 445
 carbon nanotubes, 442–443
 dendrimers, 441–442
 hybrid nanosystems, 444–445
 passive targeting, 435
 physicochemical properties
 carrier size, 445–446
 concentration and volume, 446
 lipophilicity, 447
 molecular weight, 446–447
 surface charge, 446
 polymeric carriers
 natural, 440–441
 synthetic, 441
 strategies for nanocarriers, 436–437
 surface modification on carriers
 biotin, 449, 550
 ligands, 448–449
 polyethylene glycols, 447–448
- Lymphatic vascular system
 anatomy, 431
 development of, 430
 physiology, 431
 requirements
 benefits, 432
 functions, 431–432
 targeting drugs, 433
 transport pathway, 432
- targeting
 active targeting, 436
 colloidal carriers, 436–440
 miscellaneous carriers, 441–445
 passive targeting, 435
 polymeric carriers, 440–441
 strategies for nanocarriers, 436–437
 surface modification on carriers, 447–550

- targets for delivery
 - anthrax, 434
 - cancer, 433
 - filaria, 434
 - human immunodeficiency virus, 434
 - tuberculosis, 435
- M**
- Ma, X., 398
- Macri, L.K., 636
- Macroporous scaffolds
 - bilayered/gradient scaffolds, 494–495
 - single-layered scaffolds, 492–494
- Mader, J.T., 460
- Maeda, H., 65, 67, 70
- Maehara, H., 493
- Magnetic liposomes, 106
- Magnetic nanoemulsions (MNE), 550
- Magnetic resonance imaging (MRI), 95
- Magnetic systems, GRDF, 336
- Mannose, 78–79
- Manoharan, C., 20
- Marano, R.J., 232
- Marco, J., 496
- Maretschek, S., 637
- Matrix-assisted chondrocyte implantation (MACI), 479–480
- Matrix metalloproteinases (MMPs), 70
- Matsumura, Y., 65
- McAlvin, J.B., 653–670
- McClure, C.F.W., 430
- McDevitt, M.R., 443
- McGirt, M.J., 181
- McLure, H.A., 640
- Medicated dressing, for wound healing
 - antimicrobials, 592
 - collagen-hyaluronic acid matrix, 593
 - growth factors, 593
 - vitamin A and C, 593
 - vitamin E, 593
- Meijs, G.F., 21
- Membrane transporters, intestinal tract
 - ABC superfamily, 349–352
 - drug absorption, 349
 - influx and efflux transport, 348
 - schematic diagram, 349
 - SLC, 348, 352–353
- Meng, J., 623
- Meniere's disease, 215, 216
- Mert, O., 623
- Mesenchymal stem cells
 - for osteochondral repair, 480–481
- O6-Methylguanine-DNA methyltransferase (MGMT), 172
- Microelectromechanical systems (MEMS), 182–183
- Micro-electromechanical systems (MEMS), 49
- Microparticles/Microspheres, 288
- Microporous balloon technology, 370
- MicroWick device, 219, 220
- Miller, R.E., 496
- Minami, A., 496
- Minko, T., 140
- Moddaresi, M., 552
- Mohan, N., 494
- Monoclonal antibodies, 186
- Monphytol[®] paint, 572
- Montjovent, M.O., 14
- Moses, M.A., 514
- Mouth rinse agents, 317–318
- Mouth ulcers
 - aphthous ulcers types, 293
 - Canker Cover[™], 294
 - ORABASE paste, 293
 - types of aphthous ulcers, 293
- MRP2, 350–352
- Mucoadhesive/bioadhesive systems, GRDF, 335
- Mucus barrier
 - cervicovaginal mucus, 621, 622
 - local administration, 621
 - mucoadhesive particles, 622–623
 - mucoevasive particles, 622, 624
 - poly(ethylene glycol), 623, 624
- Muntimadugu, E., 33–55
- Murdan, S., 561–579
- Myoung, Y., 576
- N**
- Nail diseases
 - nail psoriasis, 570–571
 - onychomycosis (*see* Onychomycosis)
 - symptoms, 565–566
 - topical unguinal formulations, 571
 - creams, ointments and gels, 572–573
 - films, 576
 - nail lacquers, 573–575
 - patches, 575–576
 - solutions, lotions and paints, 572
 - treatment, 566
 - diseased nails, properties of, 577
 - elimination of needle, 577
 - improved unguinal drug formulations, 577–578
 - unguinal drug permeation, 578–579

- Nail lacquers
 - antifungal, 574
 - cosmetic, 573
 - formulation of, 575
 - Loceryl and Penlac, 573, 574
 - pharmaceutical, 574–575
- Nail plate
 - composition, 563
 - constituents, 564
 - dorsal nail plate surface, 564, 565
 - growth, 563
 - keratin, 564
 - in male, 563
 - sebum, 565
 - surface properties, 564–565
- Nail psoriasis
 - intralesional drug therapy, 570–571
 - nail pitting, 570
 - photochemotherapy, 571
 - phototherapy, 571
 - topical drug therapy, 571
- Nance, E.A., 182
- NanoART, 628–629
- Nanocapsules, 232, 440
- Nanocarriers, for vaginal drug delivery
 - advantage, 619
 - antiretroviral agents, 626
 - barriers, 620
 - cervicovaginal mucus, 621, 622
 - challenges, 630–631
 - dapivirine-loaded PCL particles, 624
 - dendritic cells, 630
 - fabrication methods, 620
 - highly active antiretroviral therapy, 626
 - HIV microbicides, 625–626
 - Langerhans cells, 630
 - local administration, 621
 - mucoadhesive particles, 622–623
 - mucoevasive particles, 622, 624
 - nanoART, 628–629
 - passive targeting, 629
 - peripheral blood mononuclear cells, 628
 - pH fluctuation, 625
 - PLGA particles, 624
 - poly(ethylene glycol), 623, 624
 - poly(lactic-co-glycolic acid), 619
 - poly(propyleneimine) nanoparticles, 629
 - PSC-RANTES, 626–627
 - siRNA, 627
 - tuftsin, 629
- NANOCI project, 222
- Nano-electromechanical systems (NEMS), 49
- Nanomaterial strategies, vaginal drug delivery
 - nanocarriers, 619–631
 - nanofibers
 - applications of, 634, 635
 - biological agents, 637
 - bulk properties, 638–639
 - cellulose acetate phthalate fibers, 633–634
 - challenges, 641
 - complex geometries, 640
 - with controllable release profiles, 634–636
 - deliver nanoparticles, 638
 - economic products for global settings, 640
 - electrospinning
 - (*see* Electrospinning process)
 - PLLA and PEO blends, 634
 - three-dimensional nanofiber structure, 640
- Nanoparticle-based drug delivery system, 227–229
- Nanosuspensions, 229
- Nanotechnology
 - for arterial drug delivery
 - imaging and image-guided therapy, 379–380
 - nucleic acid delivery, 378–379
 - in small molecule drug delivery, 378
 - ophthalmic drug delivery system
 - (*see* Ocular drug delivery system)
- Nanotherapeutics, 539
 - antiacne, 551–552
 - anti-ageing, 552–554
 - antibacterial, 544–546
 - antifungal, 546–547
 - antiparasitic, 548
 - antiproliferative, 548–550
 - antiviral, 547
 - bicellar systems, 555
 - small interfering RNA, 554
 - topical immunisation, 554
- Nanovehicles ocular imaging, 235–237
- Natural polymers, 4
 - alginate, 8, 467
 - arabinogalactan, 11
 - carriers, 440–441
 - chitosan, 9–10, 467
 - collagen, 5–6, 466–467
 - dextran, 9
 - fibrin, 7
 - gelatin, 6–7, 467
 - polyhydroxyalkanoates, 11
 - silk fibroin, 8
- Negussie, A.H., 99
- Nervous system therapeutics. *See* Neuropeptides

- Neuropeptides
description, 195–196
intranasal nanoparticles, 196
issues in delivery, 200–201
nasal pathways to brain
basal cells, 197
mucous layer, 197–198
olfactory epithelium, 197
respiratory area, 196–197
vestibular region, 196
olfactory transduction, 198–199
thyrotropin-releasing hormone
cultured hippocampal neurons, 207–209
intranasal TRH-NP effect, 203
in vitro assays, 207, 210
Nile red fluorescence, 204–206
rat kindling model, 201–202
role of, 201
transneuronal transport, 198–199
uptake and transport, 199–200
- Neut, D., 464
- N*-(2-Hydroxypropyl)methacrylamide (HPMA)
copolymer conjugation, 525
- Nishiyama, N., 235
- Nitric oxide (NO), 69
- Non-focal therapies, brain tumors
angiogenesis inhibitors, 184–185
gene therapy, 185
immunotherapy and tumor vaccines,
183–184
monoclonal antibodies, 186
small-molecule inhibitors, 186
- Non-medicated dressings, for wound
healing, 590
alginate dressings, 591
hydrocolloid dressings, 591
hydrogel dressings, 591–592
- Nowacek, A.S., 628
- Nutrition, for wound healing, 599
- Nyska, M., 459–469
- O**
- Occlusive balloon technology, 370
- Ocular drug delivery system
delivery routes, 226
eye anatomy and function, 225–226
nanotechnology
cationic nanoemulsions, 229–230
dendrimers, 231–232
iontophoresis, 230–231
liposomes, 232–233
nanocapsules, 232
nanoparticles, 227–229
nanoparticulate formulations, 227–228
nanosuspensions, 229
physiological constraints, 227
solid lipid nanoparticles, 233–234
nanovehicles ocular imaging, 235–237
photodynamic therapy, 234–235
- Ocular iontophoresis
current density, 276–277
EyeGate® II delivery system, 275–276
schematic illustration, 275–276
transcorneal iontophoresis, 277–278
transscleral iontophoresis, 278–280
- Ocular nucleic acid delivery
anterior segment of eye
administration modes, 249
electroporation, 252
gene gun technology, 252
intracameral injection, 251
intrastromal injection, 250–251
iontophoresis, 253–254
physical method, 251
subconjunctival injection, 250
topical administration, penetration
enhancers, 250
type of vector, 249
antisense oligonucleotide, 248
aptamers, 249
naked DNA, 248
posterior segment of eye
electroporation, 258
injections, schematic representation,
254–255
intravitreal injection, 255–256
iontophoresis, 258–259
periocular injection, 256
subretinal injection, 254–255
tissue-specific promoter, 257
ultrasound-targeted microbubble,
257–258
viral serotypes, 257
siRNA, 248–249
structure of eye
anterior segment, 244–246
posterior segment, 246–248
schematic diagram, 244–245
- OcuPhor™, 231
- Okuda, T., 636
- Olfactory mucosa, 197, 198
- Oligo(poly(ethylene glycol) fumarate), 23
- Olive, K.P., 528
- Ommaya, A., 175, 176
- Ommaya reservoir, 175
- OncoGel™, 519
- OncoGel® system, 160

- Onychomycosis
 BATT, 569
 BOAT, 569
 classification, 566–567
 focal drug therapy, 568–569
 oral drug therapy, 567–568
 photodynamic therapy, 569
 prevalence, 566
- Ophthalmic drug delivery system. *see* Ocular drug delivery system
- Oral biofilms. *See* Biofilms
- Oral cavity
 cold sores/herpes labialis, 294–295
 extraction wounds, 298
 liquid dosage form, 289–290
 oral infections, 297
 oral malodor, 295–296
 periodontitis
 Actisite[®], 290–291
 ARESTIN[®], 292
 dentomycin[®], 292
 PerioChip[®], 291–292
 products in clinical use, 290–291
 requirements for, 286
 semisolid dosage form, 289
 solid formulations
 lozenges, 288–289
 microparticles/microspheres, 288
 tablets, 287–288
 wafers, 288
 ulcers, 293–294
 xerostomia, 298–299
- Oral drug therapy, of onychomycosis, 567–568
- Oral infections, 297
 biofilms
 controlling, 309–310
 dental caries, 308
 endodontic infections, 308–309
 formation and characteristics of, 306–307
 periodontal and peri-implant diseases, 308
 focal drug agents *vs.*
 caries lesions, 310–316
 endodontic infection, 321–323
 periodontal and peri-implant infection, 316–321
- Oral malodor, 295–296
- OraMoist[®], 287–288, 299
- Organic anion-transporting polypeptides (OATP), 353
- Orthopaedic implant devices, 37–38
- Oshima, Y., 252
- Osteoarthritis (OA), 473, 476, 496
- Osteochondral allograft transfer (OALT), 478
- Osteochondral autograft transfer (OAT), 478
- Osteochondral lesions, 473, 474, 478, 479, 482
- Osteochondral tissue
 challenges in factor administration, 485
 dual growth factor delivery system
 bilayered scaffold, 499–503
 injectable bilayer system, 503–505
 factors inducing bone regeneration
 angiogenic factors, 485
 bone morphogenic proteins, 484
 factors inducing cartilage regeneration
 bone morphogenic proteins, 483
 fibroblast growth factors, 484
 insulin-like growth factor-1, 483–484
 transforming growth factor- β , 482–483
 formation, induction of, 481
 pathophysiology, 476–477
 polymeric carriers, use of, 485
 repair
 autologous chondrocyte implantation, 479–480
 biomaterial-based delivery systems, 486–499
 microfractures, 478
 osteochondral autograft/allograft transfer, 478
 stem cell-based strategies, 480–481
 structure, 474–476
- Osteomyelitis
 antibiotic treatment
 fluoroquinolones, 462
 goal, 461
 local antimicrobial agent delivery, 461
 classification, 460
 diagnosis, 460–461
 factors, 468
 mortality and morbidity, 459
 symptoms, 460
 therapeutic drug carriers
 biodegradable implants, 463–467
 calcium phosphate/sulfate, 468
 composite scaffolds, 468
 local delivery systems, fabrication of, 462, 463
- Oussoren, C., 448
- P**
- Paasche, G., 222
- Paclitaxel, 129, 370
- Pang, Z., 80, 83
- Pant, S., 390
- PARASORB[®], 298

- Park, J., 524
- Passive lymphatic targeting, 435
- Passive microchips, 183
- Passive targeting, 63, 64, 515, 524
- Patel, H.M., 446
- Patravale, V.B., 535–555
- Pawar, P.V., 61–85
- Pawar, R.P., 459–469
- PDLA. *See* Prolonged duration local anesthesia (PDLA)
- Pegamotecan, 129–130
- Penadés, S., 630
- Peptide-based targeting, 81–82
- Percutaneous transluminal coronary angioplasty (PTCA), 365
- Perez-Davidi, M., 285–299
- PerioChip[®], 291–292
- Periodontal and peri-implant diseases, 308
- Periodontal and peri-implant therapy
- alveolar bone loss and pocket formation, 316
 - antiinfective phase, 317
 - challenges in, 320–321
 - controlled focal drug delivery, 319–320
 - dentifrices, 317
 - healthy tooth and periodontium morphology, 316
 - mouth rinse agents, 317–318
- Periodontal diseases
- Actisite[®], 290–291
 - ARESTIN[®], 292
 - dentomycin[®], 292
 - PerioChip[®], 291–292
 - products in clinical use, 290–291
- Peroxynitrites, 70
- Peterson, L., 479
- P-glycoprotein (P-gp), 349–350
- Pharmacological effects
- focal anticancer drug delivery
 - enhanced intratumoral drug distribution, 163
 - intratumoral disposition behavior, 161
 - rational design, 161–163 - pharmacodynamics, 151
 - pharmacokinetics, 149–151
 - targeted drug delivery
 - administration efficiency and clinical effectiveness, 151
 - approaches for, 153–154
 - mathematical modeling, 152–153
 - systemically administered anticancer DDSs (*see* Systemically administered anticancer DDSs)
 - terminologies, 152
- Phenytoin, for wound healing, 599
- Phillips, W.T., 448
- pH, intestinal tract (Intestinal pH)
- CODES, 347–348
 - extent of ionization, 345
 - metoprolol, 345
 - permeability measure, 345–346
 - sotalol, 346
 - values, 344
- Photodynamic therapy (PDT), 234–235
- of onychomycosis, 569
 - skin cancer, dermatological applications, 271–272
- Photofrin[®], 235
- pH-sensitive liposomes, 105–106
- Physical targeting, 515
- Physiologically based pharmacokinetic (PBPK) model, 153
- Piccirillo, S.G.M., 527
- Pigment epithelium-derived factor (PEDF)-loaded immunoliposomes, 109
- Platelet-derived growth factor (PDGF), for wound healing, 593, 596
- PLGA–PEG–PLGA triblock copolymers, 519
- Pluronic F-127, 22
- Pluronic hydrogels, 518–519
- Polak, D., 305–323
- Poly(α -hydroxy esters), 490–491
- Poly(amino acids), 22–23
- Poly(glycolic acid) (PGA), 13
- Poly(lactic acid) (PLLA), 14
- Poly(lactide-co-glycolide) (PLGA), 463–464
- Poly(*N*-isopropylacrylamide), 518
- Poly(organo-phosphazenes), 520–521
- Poly(orthoesters) (POEs), 466
- Poly(sebacic-co-ricinoleic-ester-anhydride), 465–466
- Poly(trimethylene carbonate) (PTMC), 464–465
- Polycaprolactone (PCL), 16–17
- Poly- ϵ -caprolactone (PCL), 465
- Polyethylene glycol (PEG), 491
- Polyethylene terephthalate (PET), 42
- Polyhydroxyalkanoates, 11
- Poly-lactide-co-glycolide (PLGA), 177–178
- Poly lactides (PLAs), 463–464
- Polymer-based combination therapy
- cancer stem cell, 527–528
 - multidrug resistance, 528
 - tumor angiogenesis, 528
 - tumor-associated ECM, 528
- Polymer-based drug delivery systems
- GLIADEL[®], 512, 515
 - locally injectable polymeric DDS

- Polymer-based drug delivery systems (*cont.*)
 elastin-like polypeptides, 521–522
 fatty acid-based polymers, 522–523
 thermosensitive sol–gel reversible hydrogels, 515–521
- Polymer–drug conjugates (PDC)
 advantages, 134–135
 for anticancer treatment, 525–527
 applications in cancer
 AP5346, 129
 CT-2106, 131
 DE-310, 130
 EZN-2208, 129–130
 IT-101, 130
 MAG–CPT, 128–129
 pegamotecan, 129–130
 PK1-FCE28068, 128
 PNU166148, 128–129
 PNU166945, 129
 branched polymer, 120
 classification
 end group system, 123
 hyaluronic acid, 124
 pendant group system, 123–124
 cleavable groups and applications, 126
 clinical trial, 119
 cross-linked polymers, 121
 dendrimers, 121–122, 136–139
 drug combination in, 137–141
 HPMA–antileishmaniasis conjugate, 133
 HPMA copolymer–DOX–human immunoglobulin, 132
 HPMA copolymer–doxorubicin–galactosamine, 132
 inflammatory and infectious diseases, 134
 linear polymer, 119
 linker, 125
 musculoskeletal diseases, 133–134
 physicochemical characterization, 126–127
 polymeric backbone, 125
 polymer therapeutics, 118
 prodrugs, 124
 Ringsdorf model, 122
 zidovudine–polymer conjugates, 133
- Polymer-free drug-eluting stent (DES), 395–396
- Polymeric carriers
 natural, 440–441
 synthetic, 441
- Polymeric nanocapsules, 232
- Polymeric stents, 371–372
- Polymethylmethacrylate (PMMA), 42
- Polyorthoesters (POEs), 17–18
- Porter, C.J.H., 448
- Pradilla, G., 169–186
- Price, J.S., 463
- Probiotic therapy, 315
- Prolonged duration local anesthesia (PDLA)
 drug delivery vehicles
 calcium phosphate apatite matrix, 667–668
 cyclodextrins, 665
 hybrid formulations, 666–667
 hydrogels, 664
 injectable lipid matrix, 666
 injectable liquid polymers, 665–666
 lipid-protein-sugar particles, 663
 liposomes, 660–661
 lipospheres, 663
 particulates, 659–660
 synthetic hydrophobic polymers, 661–663
 formulation properties, 654
 in humans, 669
 local anesthetics
 conventional, 655–656
 nonconventional, 656–658
 tissue reaction and systemic toxicity, 658–659
- Prostaglandins, 69–70
- Protirelin. *See* Thyrotropin-releasing hormone (TRH)
- Proximal white subungual onychomycosis (PWSO), 567
- Pseudo-poly(amino acid), 22
- Psoralen, 549
- Puttipaiboon, N., 639
- Q**
- Quick-dissolving vaginal films, 616–618
- Qureshi, S., 285–299
- R**
- Radiation therapy, GBM, 172–173
- Ramchandani, M., 464
- Ranganath, S.H., 181
- Rastogi, R., 550
- Rathbone, M.J., 607–641
- Reddy, L., 439
- Redox potential-sensitive liposomes, 106
- ReGel[®], 519
- Remineralization agents
 calcium phosphate-based systems, 311–312
 fluorides, 310–311
 toothpastes and mouthwashes, 310
- Repka, M.A., 576
- Reticuloendothelial system (RES), 134–135
- Reyes, R., 494

- Riegels-Nielsen, P., 467
Ringsdorf, H., 63, 118, 119, 122, 123
Ringsdorf model, polymer–drug conjugate
 desgin, 122
 end group system, 123
 pendent group system, 123–124
Roy, U., 628
Ruvinov, E., 473–506
- S**
- Sahoo, S.K., 225–237
Sakurai, E., 229
Salicylic acid paint, 572
Sanai, N., 171
Sankhe, K., 359–380
Santos, J.L., 137
Sarkar, S., 408
Schroeder, A., 102
Schuknecht, H.F., 216
Scott, A., 183
Second-degree wounds, 585
Second-generation DES, 389
Segal, A., 438
Segmental-dependent drug absorption and
 delivery
 intestinal tract
 classification, 343
 CYP3A4 gradient, 353–354
 membrane transporters, 348–353
 pH, 344–348
 stomach (*see* Gastroretentive dosage forms
 (GRDF))
Self-assembling peptides, 491
Sellers, R.S., 492
Semisolid vaginal dosage forms, 616, 617
Shastri, N., 117–141
Shaunak, S., 231
She, W., 218
Shikanov, A., 511–529
Shimada, M., 443
Shukla, R.S., 243–259
Silk fibroin, 8
Silverstein, H., 219
Singh, B., 335
Singh, I., 429–450
Sistla, R., 117–141, 429–450
Site-specific ocular nucleic acid delivery.
 See Ocular nucleic acid delivery
- Skin
 barrier function, 586
 cancer
 chemotherapy, 270
 photodynamic therapy, 271–272
 cellular components, 536, 537
 dermis, 536, 538, 585, 586
 epidermis, 536, 585, 586
 injuries (*see* Burns; Diabetic ulcers;
 Wounds)
 nanodelivery approach, 538–539, 545
 nanotherapeutics, 539
 antiacne, 551–552
 anti-ageing, 552–554
 antibacterial, 544–546
 antifungal, 546–547
 antiparasitic, 548
 antiproliferative, 548–550
 antiviral, 547
 bicellar systems, 555
 small interfering RNA, 554
 topical immunisation, 554
 schematic representation of, 586, 587
 thickness, 536
 topical nanodelivery system selection,
 539, 541
 topical nanoformulations
 clinical trials and market insight,
 539, 540
 literatures, 542–544
Small-angle neutron scattering
 (SANS), 127
Small molecule-based targeting ligand
 antibodies, 79–81
 aptamer, 77
 carbohydrates, 78–79
 folate-linked nanocarrier system,
 72, 76–77
 glycoproteins, 82–83
 peptides, 81–82
Solid lipid nanoparticles (SLN), 233–234,
 439–440
Solid tumor treatment. *See* Polymer-based
 drug delivery systems
Solid vaginal dosage forms, 616–617
Solute carrier family (SLC), 348
 hPepT1, 352–353
 OATP, 353
Song, S.C., 520
Song, S.J., 398
Sonoporation, 102
Souied, E.H., 259
Spray-drying methods, 662
Stabholz, A., 323
Stainless steels, 39
Staphylococcus aureus, 461
Starburst dendrimer, 121
Staudinger, H., 118
Stealth formulations, 156

- Stent therapy, arterial diseases
 biodegradable stents, 376–377
 DES, 370–371
 drug types and stent applications, 372–374
 gene-eluting stents, 377
 metallic stents
 drug-containing membrane-covered stents, 375
 drug-eluting/polymer-layer-coated stent, 375–376
 polymer-free stents, 376
 polymeric stents, 371–372
 STRESS and BENESTENT trials, 370
- Stepensky, D., 149–164
- Sterilisation, 47–48
- Stimuli-sensitive hydrogels, 515, 516
- Stojanov, K., 82
- Stupp, R., 172
- Sudden sensorineural hearing loss, 215, 216
- Sugar, antiplaque agents, 315–316
- Sugitachi, A., 7
- Suicide gene therapy, 185
- Suk, I., 169–186
- Superficial onychomycosis, 566
- Superficial partial-thickness wounds/burns.
See First-degree wounds/burns
- Superporous hydrogels, GRDF, 335
- Swami, R., 117–141, 429–450
- Synthetic polymeric carriers, 441
- Synthetic polymers, 4, 119
 poly(amino acids), 22–23
 poly(d,L-lactide-co-glycolide), 14–16
 poly(glycolic acid), 13
 poly(lactic acid), 14
 polyanhydrides, 19–20
 polycaprolactone, 16–17
 polyethylene glycol-based polymers, 21–22
 polyfumarates, 23–24
 polyorthoesters, 17–18
 polyurethanes, 21
 technological capacity, 12
- Systemically administered anticancer DDSs
 enhanced permeability of tumor, 158
 intratumoral disposition, 156–158
 pathways, 155–156
 rational design, 158–160
 strategies, 156
- T**
- Tablets, 287–288
- Takahashi, Y., 209
- Talukder, R., 334
- Tamai, N., 493
- Tamargo, R.J., 178
- Tan, E.P., 420
- Tan, W.H., 162
- Targeted drug delivery system
 EPR effect (*see* Enhanced permeability and retention (EPR) effect)
 interaction reduction, 85
 strategies, 62
 active and passive targeting, 63, 64
 triggered targeting, 63–64
 tumor heterogeneity, 84
 tumor interstitial fluid pressure, 84–85
- Temozolomide, 172, 173
- Tenofvir (TFV), 614
- Teo, W-E., 640
- Terbinafine, for onychomycosis, 567–568
- Theragnostic hydrogel, 521
- Therapeutic drug carriers
 osteomyelitis
 biodegradable implants, 463–467
 calcium phosphate/sulfate, 468
 composite scaffolds, 468
 local delivery systems, fabrication of, 462, 463
- Thermal ultrasonic effects, 99–101
- Thermosensitive sol–gel reversible hydrogels
 lower critical solution temperature
 di-/tri-/ and multiblock copolymer systems, 520
 OncoGel™, 519
 PLGA–PEG–PLGA triblock copolymers, 519
 Pluronic hydrogels, 518–519
 poly(*N*-isopropylacrylamide), 518
 poly(organophosphazenes), 520–521
 ReGel®, 519
 theragnostic hydrogel, 521
 stimuli-sensitive hydrogels, 515, 516
 upper critical solution temperature, 516–517
- Thipparaboina, R., 387–399
- Third-degree wounds/burns, 585, 587–589
- Third-generation DES, 389
- Thyrotropin-releasing hormone (TRH)
 cultured hippocampal neurons, 207–209
 intranasal TRH-NP effect, 203
 Nile red fluorescence, 204–206
 rat kindling model, 201–202
 role of, 201
 in vitro assays, 207, 210
- Tian, J.G., 15
- Tioconazole nail solution, 572
- Tissue adhesives, 7

- Tissue engineering, 474, 478, 479. *See also*
Osteochondral tissue
- Tokuhara, Y., 493
- Tomalia, D., 121
- Tooth decay, 308
- Toothpastes and mouthwashes, 310
- Topical immunisation, 554
- Topical local anesthesia, 668
- Topical microbicides, 613
- Topical skin treatments, iontophoresis
cosmeceutical applications, 274–275
dermatological applications, 268–274
devices, 268
histology, 267
- Topical unguinal formulations, nail diseases, 571
creams, ointments and gels, 572–573
films, 576
nail lacquers
antifungal, 574
cosmetic, 573
formulation of, 575
Loceryl and Penlac, 573, 574
pharmaceutical, 574–575
patches, 575–576
solutions, lotions and paints, 572
- Torabinejad, M., 323
- Torchilin, V.P., 80, 93–110
- Total dystrophic onychomycosis (TDO), 567
- Total parenteral nutrition (TPN), for wound
healing, 599
- Transcorneal iontophoresis, 277–278
- Trans-eustachian tube catheter injections,
218–219
- Transferrin, 82–83
- Transforming growth factor- β (TGF- β),
482–483
- Transscleral iontophoresis, 278–280
- Transtympanic catheter injections, 218
- Transtympanic needle injections, 217
- Tantrum, J.R., 236
- Trapani, A., 10
- Triggered targeting, 63–64
- Tsuchida, K., 443
- Tubic-Grozdanic, M., 354
- Tufts, 629
- Tumor interstitial fluid pressure (TIFP), 84–85
- Tyler, B.M., 169–186
- Tympanic medial wall diffusion, 221–222
- TyroSpheres™, 549, 550
- U**
- Uher, M., 124
- UK guidelines, DES, 394
- Ulbrich, K., 124
- Ultrahigh molecular weight polyethylene
(UHMWPE), 42
- Ultrasound-mediated liposomal FDD
actively targeted liposomes, 104–105
light-responsive liposomes, 106–107
magnetic liposomes, 106
pH-sensitive liposomes, 105–106
redox potential-sensitive liposomes, 106
- Umamaheshwari, R.B., 337
- Umbilical cord-derived stem cells, for wound
healing, 597
- Ungual drug permeation, nail diseases
after topical application, 578
enhancement of, 578–579
- Upper critical solution temperature (UCST)
thermosensitive hydrogels, 516–517
- US guidelines, DES, 394
- Ushakov, S., 119
- V**
- Vaccines, antiplaque agents, 314–315
- Vagina
drug candidates and absorption
absorption mechanisms, 611–612
physicochemical properties, 611
drug delivery systems, 612
gross anatomy of, 608–609
physiology of
blood supply, 609
vaginal fluid, 609–611
- Vaginal drug delivery systems
goals of, 617, 618
nanomaterial strategies for
nanocarriers, 619–631
nanofibers, 631–641
programming drug release, 618
rational design of
pharmacological considerations, 614
physical and biological evaluation,
615–618
tissue and cellular targets for HIV, 613
- Vaginal fluid
enzymes, 611
microflora, 611
mucus, 610
origin and contents, 609
pH, 610
volume, 610–611
- Van Leeuwen, A.C., 464
- Vandamme, T.F., 231
- Variola, F., 399
- Varshosaz, J., 9

Vascular endothelial growth factor (VEGF),
70–71
Veronesi, M.C., 195–211
Verreck, G., 637
Vicent, M.J., 126
Videira, M.A., 440
Visudyne®, 235
Visulex™, 231
Vlieghe, P., 133
Vogtle, F., 121

W

Wafers, 288
Wagner, A., 125
Wagner-Meggitt classification, 589
Wang, D., 134
Wang, Y-Y., 623
Weber, L., 217
Weinberger, J.Z., 387–399
Weiss, E.I., 285–299
Wen, S.F., 250
Wenk, E., 8
Westedt, U., 416
Williamson, M.R., 17
Wimmer, N., 231
Wirtz, R., 275
Wittrup, K.D., 159
Wolk, O., 329–338, 343–355
Woodrow, K.A., 607–641
Woolfson, D., 612
Wosikowski, K., 132
Wounds

acute vs. chronic, 588–589
acute wound healing
inflammation, 587
proliferative phase, 587
remodeling phase, 587–588
chronic (*see* Diabetic ulcers)
drug delivery
antibiotics, 594–595
antihistamines, 599
antioxidants, 598
ayurvedic herbal plants, 600
connexin-targeted antisense gel, 599–600
dressings, 589–593
gabapentin, 599

gene therapy and cytokines, 595–596
growth factors, 596–597
nutritions, 599
phenytoin, 599
reactive oxygen species, 598
stem cells, 597–598
traditional drugs, 600
first-degree, 585
second-degree, 585
third-degree, 585–586

Wu, W.T., 527

X

Xerostomia, 298–299
Xie, J., 636
Xu, P., 205, 207

Y

Yamazaki, T., 218
Yan, W., 493
Yang, J., 399
Yang, L., 336
Yang, Z., 415
Ye, C., 11
Yenice, I., 467
Yield strength, 45
Yoo, H.S., 639
Yoo, J-W., 625
Youshia, J., 233
Youssefian, S., 399
Yu, A., 547
Yu, D-G., 637
Yu, T., 624
Yu, Y., 83
Yue, Y., 552

Z

Zhang, Q.Y., 218
Zhang, T., 625
Zhang, Y., 81
Zhao, J., 17
Zidovudine, 133
Zirconia ceramics, 44
Zou, J., 215–223